Subtype
Kidney Neoplasm
CI-CAN-00002988Explore in graph →
Non-malignant481 active trials17 approved drugs80 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002988Explore in graph →
Clinical trials
2,320 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04764487 | A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line(AxiPRO) | unknown | Phase 3 | 178 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT02928692 | Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium(MAPOCD) | unknown | Phase 3 | 750 | RenJi HospitalOTHER | 1 | Jan 28, 2020 |
| clinicaltrials |
| NCT01099423 | Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer(SURTIME) | unknown | Phase 3 | 99 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Feb 8, 2017 | clinicaltrials |
| NCT00003804 | Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor | unknown | Phase 3 | 350 | University of LeicesterOTHER | 15 | Jun 24, 2014 | clinicaltrials |
| NCT00047138 | Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor | unknown | Phase 3 | 350 | University of LeicesterOTHER | 4 | Jun 24, 2014 | clinicaltrials |
| NCT01481870 | Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma(CROSS-J-RCC) | unknown | Phase 3 | 120 | Yamagata UniversityOTHER | 1 | Feb 25, 2013 | clinicaltrials |
| NCT00869011 | Exercise for Patients With Renal Cell Cancer Receiving Sunitinib | unknown | Phase 3 | 70 | Charite University, Berlin, GermanyOTHER | 1 | Dec 23, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 3, 2022source: clinicaltrials